130 related articles for article (PubMed ID: 21502798)
21. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
Fukuda T; Yokoyama N; Tamai M; Imaizumi M; Kimura H; Tominaga T; Ashizawa K; Kiriyama T; Yoshimine H; Ohishi K; Eguchi K
Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
[TBL] [Abstract][Full Text] [Related]
22. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
23. Use of somatostatin analogue in management of a thyrotrophin secreting pituitary adenoma.
Stiles MK; Conaglen JV; Speed J; Chatterton B
Aust N Z J Med; 1996 Feb; 26(1):122-3. PubMed ID: 8775545
[No Abstract] [Full Text] [Related]
24. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
[TBL] [Abstract][Full Text] [Related]
25. TSH secreting pituitary adenoma: a rare cause of thyrotoxicosis.
So WY; Yeung VT; Chow CC; Ko GT; Szeto CC; Cockram CS
Int J Clin Pract; 1998; 52(1):62-4. PubMed ID: 9536575
[TBL] [Abstract][Full Text] [Related]
26. [Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma].
Chen S; Li M; Lian XL; Zeng ZP; Dai WX; Li F; Yu W; Wang RZ
Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):910-3. PubMed ID: 17313878
[TBL] [Abstract][Full Text] [Related]
27. Acute liver injury and octreotide.
González-Martín JA; Donnay S; Morillas J; Gómez-Aparicio C; Garcia-Cano J; Pérez-Vigara G; Roldán A
Am J Gastroenterol; 1996 Nov; 91(11):2434-5. PubMed ID: 8931436
[TBL] [Abstract][Full Text] [Related]
28. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
29. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
30. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment.
Kurosaki M; Saegert W; Abe T; Lüdecke DK
Neurol Res; 2008 Jun; 30(5):518-22. PubMed ID: 18953743
[TBL] [Abstract][Full Text] [Related]
31. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy.
Blackhurst G; Strachan MW; Collie D; Gregor A; Statham PF; Seckl JE
Clin Endocrinol (Oxf); 2002 Sep; 57(3):401-4. PubMed ID: 12201834
[TBL] [Abstract][Full Text] [Related]
32. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
33. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
34. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
[TBL] [Abstract][Full Text] [Related]
35. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Harinarayan CV
J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
[TBL] [Abstract][Full Text] [Related]
36. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
37. [Response of thyrotropinoma to somatostatin analogues: report of a case].
García Lafuente N; Berná Gascón MT; Pujalte López E; Falcó Jover G; Domínguez Escribano JR
An Med Interna; 2001 Dec; 18(12):663. PubMed ID: 11852512
[No Abstract] [Full Text] [Related]
38. Pituitary gigantism: a retrospective case series.
Creo AL; Lteif AN
J Pediatr Endocrinol Metab; 2016 May; 29(5):597-602. PubMed ID: 26887033
[TBL] [Abstract][Full Text] [Related]
39. [Pituitary adenoma in acromegaly-gigantism. Macroscopic, histological and ultrastructural study].
Robert F
Neurochirurgie; 1973 May; 19(2):Suppl 2:117-62. PubMed ID: 4356509
[No Abstract] [Full Text] [Related]
40. [Pituitary adenoma treated with a somatostatin analog].
Houdent C; Armangau MF; Kuhn JM; Delangre T; Tadie M; Clavier E; Basuyau JP; Sassolas G; Wolf LM
Ann Endocrinol (Paris); 1989; 50(3):227-31. PubMed ID: 2817765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
